Piramal Pharma Solutions (India) and Ajinomoto Bio-Pharma Services (Japan) have announced a strategic collaboration to enhance the development and manufacturing of Antibody-Drug Conjugates (ADCs), one of the most advanced therapeutic classes in oncology.
Strategic Framework and Technology Transfer: The collaboration creates a reciprocal support system for pharmaceutical developers:
-
Service Ecosystem: Piramal will refer customers requiring specialized ADC technology to Ajinomoto’s AJICAP™ platform. In turn, Ajinomoto will recommend Piramal as a preferred CDMO partner for manufacturing products developed using this technology.
-
Material Transfer Agreement (MTA): A separate agreement will facilitate technology transfer, equipping Piramal with the expertise and personnel needed to manufacture AJICAP™-based products with enhanced precision and efficiency.
Strengths of the Partners:
-
Piramal Pharma: As the world’s first FDA-approved ADC CDMO, Piramal brings over two decades of experience. The company has pioneered commercial ADC manufacturing, completing thousands of batches across its global network of advanced facilities.
-
Ajinomoto Bio-Pharma: Its proprietary AJICAP™ technology enables site-specific conjugation and simplified linker processes. This platform helps developers create ADCs with improved efficacy and reduced toxicity compared to traditional conjugation methods.
Strategic Vision: By combining Ajinomoto’s site-specific technology with Piramal’s large-scale GMP manufacturing expertise, the partnership aims to accelerate development timelines and streamline the transition from early-stage research to commercial production. This synergy is expected to provide global patients with faster access to high-quality, precise ADC therapies.